Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
IPO Year: 2019
Exchange: NASDAQ
Website: frequencytx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/15/2023 | Buy → Neutral | Chardan Capital Markets | |
| 2/13/2023 | Outperform → Market Perform | Cowen | |
| 9/22/2021 | $12.00 → $9.00 | Buy → Neutral | Goldman Sachs |
Chardan Capital Markets downgraded Frequency Therapeutics from Buy to Neutral
Cowen downgraded Frequency Therapeutics from Outperform to Market Perform
Goldman Sachs downgraded Frequency Therapeutics from Buy to Neutral and set a new price target of $9.00 from $12.00 previously
Oppenheimer reiterated coverage of Frequency Therapeutics with a rating of Outperform and set a new price target of $20.00 from $68.00 previously
Oppenheimer reiterated coverage of Frequency Therapeutics with a rating of Outperform and set a new price target of $68.00 from $48.00 previously
JP Morgan upgraded Frequency Therapeutics from Neutral to Overweight and set a new price target of $56.00
Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio's wholly owned portfolio of RNA editing programs Lead program is a disease modifying therapy for patients with alpha-1 antitrypsin deficiency (AATD), with preclinical data showing an increase of normal A1AT protein to 85% of total protein in circulation Combined company is expected to have cash balance of approximately $170 million at close, which is expected to provide cash runway through several value-creating milestones and into 2026 Companies to host conference call today at 8:30 a.m. ET Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel geneti
4 - Korro Bio, Inc. (0001703647) (Issuer)
3 - Korro Bio, Inc. (0001703647) (Issuer)
4 - Korro Bio, Inc. (0001703647) (Issuer)
3 - Korro Bio, Inc. (0001703647) (Issuer)
3 - Korro Bio, Inc. (0001703647) (Issuer)
3 - Korro Bio, Inc. (0001703647) (Issuer)
3 - Korro Bio, Inc. (0001703647) (Issuer)
3 - Korro Bio, Inc. (0001703647) (Issuer)
3 - Korro Bio, Inc. (0001703647) (Issuer)
3 - Korro Bio, Inc. (0001703647) (Issuer)
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business
Company Announces Appointment of Jeffery Lichtenhan, Ph.D., to Lead Efforts in Hearing Diagnostics and Measurement; Joins Frequency from Washington University Medical School in St. Louis Frequency Therapeutics, Inc. (NASDAQ:FREQ), a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the expansion of its clinical development team with the addition of Jeffery T. Lichtenhan, Ph.D., a leading expert in hearing diagnostics and measurement. Dr. Lichtenhan, an auditory neuroscientist, will help to advance the Company's hearing clinical development programs, including it
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the appointment of Kevin Franck, Ph.D., as Senior Vice President of Strategic Marketing and New Product Planning. Dr. Franck will lead pre-commercial strategy and launch planning for Frequency’s clinical pipeline, including its lead program aimed at developing a restorative treatment for sensorineural hearing loss (SNHL), the most common form of hearing loss. Dr. Franck is a leader in the hearing field with 25 years of experienc
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the appointment of Quentin McCubbin, Ph.D., as chief manufacturing officer. Dr. McCubbin will oversee Company technical operations, leading drug product formulation, chemistry manufacturing and controls (CMC) and supply chain, to support the development of Frequency’s pipeline of product candidates. Dr. McCubbin joins Frequency from Cerevel Therapeutics, a clinical-stage biotechnology company where he served as head of technical
WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that it has named Peter P. Pfreundschuh as its new chief financial officer. Mr. Pfreundschuh will oversee the Company’s financial strategy and activities related to accounting, investor relations, business development and business operations. Mr. Pfreundschuh joins Frequency from UroGen Pharma Ltd., a commercial-stage biopharma company, where he served as chief financial officer, chief compliance officer and corporate secretary.
NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business
Korro will be focused on advancing a wholly owned portfolio of RNA editing programsPost-transaction cash of approximately $170 million expected to fund operations into 2026Funds multiple potentially value-creating milestones, including advancing its lead product candidate in Alpha-1 antitrypsin deficiency (AATD) through a clinical trialShares to trade on Nasdaq under the ticker "KRRO" commencing on November 6, 2023 CAMBRIDGE, Mass. and LEXINGTON, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling treatment of both r
Frequency Therapeutics, Inc. (NASDAQ:FREQ) today announced business updates and financial results for the second quarter ended June 30, 2023. In July, the Company announced that it entered into a definitive merger agreement with Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel genetic medicines. After the anticipated consummation of the merger, the combined company will operate under Korro Bio, Inc. with a focus on the advancement of Korro Bio's portfolio of RNA editing programs and will trade on Nasdaq under the ticker symbol "KRRO." The merger is expected to close in the fourth quarter of 2023, subject to approval by Frequency Therapeutics
NEW YORK, July 15, 2023 (GLOBE NEWSWIRE) -- Great Ajax Corporation (NYSE:AJX) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of AJX to Ellington Financial Inc. for 0.5308 shares of Ellington Financial Inc. common stock for each share of AJX common stock owned. If you are an AJX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. American Equity Investment Life Holding Company (NYSE:AEL) Lifshitz Law PLLC announces an investigation into possible br
Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio's wholly owned portfolio of RNA editing programs Lead program is a disease modifying therapy for patients with alpha-1 antitrypsin deficiency (AATD), with preclinical data showing an increase of normal A1AT protein to 85% of total protein in circulation Combined company is expected to have cash balance of approximately $170 million at close, which is expected to provide cash runway through several value-creating milestones and into 2026 Companies to host conference call today at 8:30 a.m. ET Korro Bio, Inc., a leading RNA editing company focused on the discovery and development of novel geneti
Frequency Therapeutics, Inc. (NASDAQ:FREQ), a regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore function, today announced business updates and financial results for the first quarter ended March 31, 2023. "We are pleased with the team's progress in advancing our program for remyelination in multiple sclerosis and we remain on track to commence our clinical program in the first half of 2024. We have now shown that Frequency's novel compounds can drive oligodendrocyte differentiation in evolutionarily distinct species, furthering our ability to predict human doses, and have independently conducted preclinical studies demonstr
Frequency Therapeutics, Inc. (NASDAQ:FREQ), a regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore function, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2022. "The Frequency team continues to make important progress with our novel therapeutic program designed to induce remyelination for individuals living with multiple sclerosis and remains on track to initiate clinical development for a potentially first-in-class therapy for this debilitating disease in the first half of 2024. Our current cash position takes us into Q1 2025, which enables us to advance developm
Frequency Therapeutics, Inc. (NASDAQ:FREQ), a regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore function, today announced that interim Chief Executive Officer and Chief Scientific Officer Christopher Loose, Ph.D., will present at the following March healthcare investor conferences: 43rd Annual Cowen Healthcare Conference: Dr. Loose will participate on a panel discussion on March 8th at 12:50 p.m. ET. 33rd Annual Oppenheimer (Virtual) Healthcare Conference: Dr. Loose will provide a Company overview on Monday March 13th at 8:00 a.m. ET. Live conference webcasts can be accessed on the Investors and Media section of the Compan
FX-322-208 Study Fails to Meet Primary Endpoint, Showing No Significant Separation in Speech Perception Between FX-322 and Placebo Company Will Now Focus on Advancing its Program in Remyelination for Multiple Sclerosis (MS) Announces Corporate Restructuring and Will Also Explore Strategic Financing Alternatives; Net of Debt, has Cash and Marketable Securities of $68.9mm as of December 31, 2022 Frequency Therapeutics, Inc. (NASDAQ:FREQ), a regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore function, today announced clinical results from the placebo-controlled Phase 2b study of FX-322 in individuals with acquired Sensorineura
Global Neurology Leaders to Support Development of a Potentially Restorative Treatment for MS as Program Advances Toward 2023 Regulatory Filing Company also Expands Regenerative Medicine Advisory Board with Addition of Nobel Laureate and Cell Biologist Dr. James Rothman Frequency Therapeutics, Inc. (NASDAQ:FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate potential to restore function, today announced that it has established a Clinical Advisory Board to help guide its remyelination in multiple sclerosis (MS) program. Comprised of leading experts from across the neurosciences, the Clinical Advisory Board will support clin
SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)
SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)
SC 13G - Korro Bio, Inc. (0001703647) (Subject)
SC 13G - Korro Bio, Inc. (0001703647) (Subject)
SC 13G - Korro Bio, Inc. (0001703647) (Subject)
SC 13D - Korro Bio, Inc. (0001703647) (Subject)
SC 13G - Korro Bio, Inc. (0001703647) (Subject)
SC 13G - Korro Bio, Inc. (0001703647) (Subject)
SC 13G - Korro Bio, Inc. (0001703647) (Subject)
SC 13D - Korro Bio, Inc. (0001703647) (Subject)
424B3 - Korro Bio, Inc. (0001703647) (Filer)
8-K - Korro Bio, Inc. (0001703647) (Filer)
EFFECT - Korro Bio, Inc. (0001703647) (Filer)
424B3 - Korro Bio, Inc. (0001703647) (Filer)
S-1/A - Korro Bio, Inc. (0001703647) (Filer)
S-1/A - Korro Bio, Inc. (0001703647) (Filer)
8-K - Korro Bio, Inc. (0001703647) (Filer)
S-8 - Korro Bio, Inc. (0001703647) (Filer)
S-3 - Korro Bio, Inc. (0001703647) (Filer)
8-K - Frequency Therapeutics, Inc. (0001703647) (Filer)